The binding of VCE-004.3 to CB 1 and CB 2 receptors and PPARγ and its effect on their functional activities were studied in vitro and in silico. Anti-fibrotic effects of VCE-004.3 were investigated in NIH-3T3 fibroblasts and human dermal fibroblasts. To assess its anti-inflammatory and anti-fibrotic efficacy in vivo, we used two complementary models of bleomycin-induced fibrosis. Its effect on ERK1/2 phosphorylation induced by IgG from SSc patients and PDGF was also investigated.
Introduction
Systemic sclerosis (SSc) or scleroderma is a chronic multiorgan autoimmune disease of unknown aetiology characterized by vascular, immunological and fibrotic abnormalities. The disease is complex and dynamic, and the interrelationship among the three main hallmarks of SSc results in a wide spectrum of clinical presentations ranging from limited skin involvement [limited cutaneous SSc (lcSSc) ] to widespread internal organ fibrosis [diffuse cutaneous SSc (dcSSc) ]. The pathogenesis of SSc is not fully understood, and it is believed that inflammation as well as vascular injury in the initial stages drive the autoimmune response and precede fibrosis in the course of the disease (Varga and Abraham, 2007; Pattanaik et al., 2015) .
Several lines of evidence have shown that the endocannabinoid system (ECS) may play a role in the physiopathology of SSc. Cannabinoids exert a broad range of biological activity including anti-inflammatory effects (Katchan et al., 2016) , effects on endothelial function (Bouchard et al., 2003) and cell death regulation (Garcia- Gonzalez et al., 2009 ). The ECS is composed of cannabinoid receptors, CB 1 and CB 2 , their endogenous lipid ligands represented by anandamide (AEA) and 2-arachidonoylgylcerol (2-AG) and the enzymes responsible for their degradation (Pacher et al., 2006) . CB 1 and CB 2 receptors are overexpressed in SSc fibroblasts (Garcia- Gonzalez et al., 2009) , and the antiinflammatory and anti-fibrotic actions of cannabinoids have been widely demonstrated both in vitro and in vivo. Thus, inactivation of CB 1 receptors decreased the number of infiltrating T-cells and macrophages in lesioned skin (Marquart et al., 2010) . In contrast, CB 2 receptor activation limits leukocyte infiltration and tissue fibrosis (Akhmetshina et al., 2009) . Thereby, structurally different CB 2 agonists such as ajulemic acid, JHW-133 and VCE-004.8 have been shown to alleviate skin fibrosis and inflammation in experimental SSc (Akhmetshina et al., 2009; Gonzalez et al., 2012; del Rio et al., 2016) .
In addition to binding to classical CB 1 and CB 2 receptors, some natural and semisynthetic cannabinoids also bind and activate the nuclear hormone receptor PPARγ (Pistis and O'Sullivan, 2017) . PPARγ was initially identified through its role in the regulation of glucose and lipid metabolism and cell differentiation, but it is now well established that PPARγ agonists are also exhibit anti-inflammatory and anti-fibrotic effects (Clark, 2002; Dantas et al., 2015) . In this regard, PPARγ is a regulator of connective tissue homeostasis, and different experimental approaches have shown that PPARγ ligands attenuate hepatic (Galli et al., 2002) , renal (Bae et al., 2017) and pulmonary fibrosis (Milam et al., 2008) as well as bleomycin-induced skin fibrosis (Gonzalez et al., 2012; Wei et al., 2014; del Rio et al., 2016; Ruzehaji et al., 2016) .
Different serum autoantibodies against multiple intracellular antigens have been detected and proposed as biomarkers for early and precise diagnosis in SSc (Kayser and Fritzler, 2015) . However, how autoantibodies contribute to the prognosis of SSc is not fully understood. Autoantibodies directed against non-nuclear autoantigens including anti-PDGF receptor, anti-endothelial cells, anti-fibroblast and anti-angiotensin type 1-receptor autoantibodies with possible pathogenic properties have been also described (Ho and Reveille, 2003; Baroni et al., 2006; Fineschi et al., 2008; Mihai and Tervaert, 2010; Kayser and Fritzler, 2015) .
Hence, targeting the ECS and PPARγ, which are considered potential therapeutic targets in SSc, represents a viable approach to prevent or attenuate inflammation and fibrosis in SSc. In the present study, we demonstrated that the novel cannabidiol (CBD) aminoquinone derivative VCE-004.3, which targets PPARγ and CB 2 receptors, but also antagonizes CB 1 receptors, exhibits anti-inflammatory and anti-fibrotic effects.
Methods

Cell lines
HEK-293T, HEK-293T-CB 1 , HEK-293T-CB 2 , NIH-3T3 and normal human dermal fibroblasts (NHDFs) were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. All cells were maintained at 37°C and 5% CO 2 in a humidified atmosphere.
VCE-004.3 synthesis
VCE-004.3 was synthesized by oxidizing CBD with the hypervalent iodine reagent SIBX as previously described (del Rio et al., 2016) and then trapping it with n-pentylamine (four molar equivalents) in ethanol solution (ca. 6 mL·mmol À1 of quinone). The mixture was stirred at room temperature for 18 h, diluted with water (1:5), acidified to pH = 2 with HCl (10% aqueous solution) and then extracted with CH 2 Cl 2 (30 mL). The organic layer was dried (Na 2 SO 4 ), filtered and concentrated, and the residue was purified by reverse phase chromatography (30 at 100% CH 3 CN and was measured following a previously described procedure (Ragusa et al., 2015) . Competition binding data were analysed by using GraphPad Prism ® version 5.01 (GraphPad Software Inc., CA, USA).
Docking analysis
Docking analysis was performing using AutoDock4 (Morris et al., 2009) and Vina softwares (Trott and Olson, 2010) with the virtual screening tool PyRx (Wolf, 2009) and PyMOL (Baugh et al., 2011) . The receptor model used was the Protein Data Bank (PDB) reference (RCSB PDB accession code), 3B0R (Hughes et al., 2014) , and 5U5L (Rajapaksha et al., 2017) . The search space for the docking was set according to previous findings about several binding sites for different ligands. After analysis, AutoDock Vina provides the estimated binding affinity value, which is the sum of the intermolecular energy and the torsional free-energy penalty. A negative value indicates that a bond is thermodynamically stable, whereas a positive value means it is unstable. Search space for the docking was set around the binding sites described previously (Hughes et al., 2014) .
Cytotoxicity assay
NIH-3T3 (1 × 10 3 cells) were seeded in 96 well plates and after 24 h incubated with VCE-004.3 for another 6 h in the presence of 0.1 μM YOYO-1 (Life Technologies). The survival of untreated cells was considered to be 100%. Fluorescence was measured using an Incucyte FLR imaging system (Essen BioScience, Ann Arbor, MI, USA).
Transfections and luciferase assays
HEK-293T (8 × 10 4 ) cells stably expressing human cannabinoid CB 1 or CB 2 receptors were seeded in 24-well plates and after 24 h were transiently transfected with the pCRE-luc plasmid (0.2 μg per well) using Roti © -Fect (Carl Roth, Karlsruhe, Germany) following the manufacturer's instructions. The cAMP response element (CRE) luciferase reporter contains the firefly luciferase gene under the control of multimerized CRE located upstream of a minimal promoter. Twenty-four hours after transfection, CB 1 -HEK-293T cells were pretreated for 30 min with VCE-004.3 and stimulated with WIN55,212 (1 μM) for 6 h. CB 2 -HEK-293T cells were pretreated for 30 min with VCE-004.3 or WIN55,212 as positive control and stimulated with forskolin (10 μM) for 6 h. NIH-3T3 (5 × 10 4 ) cells were seeded in 24-well plates and after 24 h were transiently transfected with the indicated constructs (PPARγ-GAL4, 0.2 μg; PPARα-GAL4, 0.2 μg; PPARδ-GAL4, 0.2 μg; GAL4-luc, 0.8 μg; or CAGA-luc, 0.5 μg). NIH-3T3 stably expressing Col1A2-luc were seeded in 24-well plates (5 × 10 4 cells per well) and treated as indicated. After treatments, luciferase activity was measured using a Dual-Luciferase Assay (Promega, Madison, WI, USA).
Measurement of collagen secretion and accumulation
NHDFs were seeded in 24-well plates (5 × 10 4 cells per well), pretreated with VCE-004.3 for 1 h and stimulated with 
Animal experiments
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . A total of 90 BALB/C female mice (6-8 weeks old) weighing between 17 and 20 g (Envigo, Valencia, Spain) were used in the studies. Experiments were performed in accordance with European Union guidelines and were approved by the Animal Research Ethic Committee of Córdoba University and the Andalusian Committee for Animal Experimentation (2014PI/016). Mice were housed in groups of nine animals in polycarbonate cages (300 mm × 180 mm × 150 mm) with free access to food and water, in the animal facilities of the University of Córdoba, and maintained in a 12 h light/dark cycle with controlled temperature (20 ± 2°C) and relative humidity (40-50%) (McGrath and Lilley, 2015) .
Different administration schedules of s.c. bleomycin (BLM) have been widely used as SSc models. Repetitive injections of s.c. BLM induce skin fibrosis localized to the injection area and lead to systemic symptoms such as lung fibrosis (Beyer et al., 2010) . Two different BLM-induced models were used to assess the effects of VCE-004.3 in vivo.
(i) The inflammatory model of SSc was used to study the preventive effects of VCE-004.3. Fibrosis was induced by daily s. c. administration of BLM (50 μg per mice; 100 μL) (Mylan, Barcelona, Spain) for 3 weeks. Treatments were administered in parallel and consisted of daily i.p. injections of VCE-004.3 (20 mg·kg À1 ), RGZ (5 mg·kg À1 ) or vehicle (4% DMSO, 6.2% Tween 20, saline; 100 μL). S.c. injections of 0.9% NaCl served as a control.
(ii) A pre-established fibrosis model of SSc was induced to study the curative effect of VCE-004.3. Fibrosis was induced by daily s.c. injections of BLM (20 μg per mice; 100 μL) for 6 weeks. After 3 weeks of BLM administration, animals were treated in parallel with a daily i.p. injection of VCE-004.3 (20 mg·kg À1 ), RGZ (5 mg·kg À1 ) or vehicle or were given topical application of VCE-004.3 (250 μM) or vehicle (7:3 polypropylene glycol : ethanol; 100 μL) for the remaining 3 weeks. Mice were acclimatized to manipulators for a week before the experiments in order to reduce stress and allow the detection of subtle changes in behaviour by researchers. Mice weight was evaluated weekly, and no significant changes were observed between experimental groups. No behavioural changes were observed during the protocols. Neither piloerection nor hunched appearances were apparent during the experimental procedures. Mice were killed by cervical dislocation, and the back skin was removed and processed for histological examination or was frozen for further analysis. Macroscopic evaluation of internal organs did not reveal any pathological changes.
Blinding and randomization
Laboratory animals were randomly assigned to experimental groups, and treatments were assessed by a blinded investigator. The order of treatment administration was also randomized. All animal samples were studied, and analysis was carried out in a blinded manner. For immunohistochemical studies, three random fields of each skin biopsy were photographed and evaluated by two independent observers.
Histochemical analysis
Skin sections (5 μm-thick) were stained with Masson's trichrome, picrosirius red or toluidine blue. Myofibroblasts were detected in skin sections by immunofluorescent labelling with α-SMA (1:50, sc-32 251, Santa Cruz) and Alexa 488 (A-11008; Life Technologies). For quantification, images were taken with a LSM 5 Exciter confocal microscope (Zeiss, Jena, Germany) and quantified in 10 to 15 randomly chosen fields at 250 magnification using ImageJ software (http:// rsb.info.nih.gov/.ij). For immunohistochemical detection of macrophages, T-cells and ERK1/2 activation, we used F4/80 (1:50; MCA497, Bio-Rad), CD3 (1:100, sc20047, Santa Cruz) and p-ERK 1/2 (1:100; sc-7383, Santa Cruz) antibodies respectively. Slides were developed with diaminobenzidine chromogen (Merck Millipore) and counterstained with Harris haematoxylin solution. Slides were photographed, digitized using a Leica DFC420c camera and analysed using ImageJ software.
Real-time PCR
Total RNA was isolated from mice frozen skin tissue using QIAzol Lysis Reagent (Qiagen, Hilden, Germany) and purified with RNeasy Mini Kit (Qiagen). Total RNA (1 μg) was retrotranscribed using the iScript™ cDNA Synthesis Kit (BioRad), and the cDNA generated was analysed by real-time PCR using the iQTM SYBR Green Supermix (Bio-Rad) using a CFX96 Real-Time PCR Detection System (Bio-Rad). The oligonucleotide primers used are listed in Supporting Information Table S1 . Gene expression was normalized to GADPH mRNA levels in each sample and expressed using the 2 ÀΔΔCt method.
Patients and IgG antibodies purification
In total, 12 patients, six with lSSc and six with dSSc, were included in the study after ethics committee approval. All subjects provided written informed consent. Samples were obtained from peripheral venous blood. IgGs were purified using a pool of six patients with lcSSc and six patients with dSSc using high affinity chromatography of G-sepharose protein (MabTrap, GE Healthcare Bio-Sciences AB, Uppsala, Sweden) following the manufacturer's recommendations.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . In vitro results are shown as mean ± SD and in vivo data as mean ± SEM. Statistical analysis was carried out using the SPSS v.19 software for Windows (IBM Corporation, New York, USA). Results were tested for normal distribution using Kolmogorov-Smirnov normality test. Then, data were analysed using one-way ANOVA followed by Tukey's post hoc test when F achieved was P < 0.05, and there was no significant variance in homogeneity. Some results were normalized to control to avoid unwanted sources of variation. Differences between not normally distributed results were studied by the Kruskall-Wallis followed by Dunn's post hoc test using the GraphPad Prism v.5 for Windows. Minimal statistical significance was set at P < 0.05.
Materials
Rosiglitazone (RGZ) was from Cayman Chem (Ann Arbor, MI, USA), TGFβ1 was obtained from Immunotools GmbH (Friesoythe, Germany) and non-immunized human IgG was from Jackson Immunoresearch (West Grove, PA, USA). All other reagents were purchased from Sigma Co (St Louis, MO, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
VCE-004.3 is a CBD quinone derivative with selective PPARγ and CB 2 agonism and CB 1 antagonism
We have previously shown that VCE-004.8, a dual PPARγ/CB 2 agonist, alleviates dermal fibrosis through PPARγ and CB 2 receptor-dependent pathways in a mice model of SSc (del Rio et al., 2016). As part of our programme of chemical synthesis searching for CBD quinone derivatives, we selected the novel compound VCE-004.3 ( Figure 1A ) and investigated its mechanism of action and efficacy in dermal inflammation and fibrotic events. Firstly, we evaluated the binding affinity to PPARγ and found that VCE-004.3 was able to bind PPARγ with an IC 50 of 3.5 μM, which is a significantly lower affinity than the binding of RGZ ( Figure 1B) . VCE-004.3 was not cytotoxic and induced PPARγ transcriptional activity in a concentration-dependent manner in NIH-3T3 cells transiently co-transfected with GAL4-luc and PPARγ-GAL4 plasmids ( Figure 1C ). However, VCE-004.3 did not activate PPARα ( Figure 1D ) or PPARδ ( Figure 1E ) transcription, indicating that VCE-004.3 is a selective agonist of the PPARγ isoform.
To further characterize the effects of VCE-004.3 on PPARγ transcriptional activities, we performed experiments to study the behaviour of VCE-004.3 in the presence of RGZ. To this end, GAL4-PPARγ/GAL4-luc transfected NIH-3T3 cells were preincubated with increasing concentrations of VCE-004.3 and then treated with 1 μM RGZ. VCE-004.3 decreased the RGZ-induced PPARγ transactivation (Figure 2A ), suggesting that VCE-004.3 could prevent RGZ binding by competing with the same binding site on PPARγ. Moreover, the stimulating effect on PPARγ was eliminated after removal of VCE-004.3 by washing cells with PBS, suggesting that VCE-004.3 binds to PPARγ in a reversible and non-covalent manner ( Figure 2B ).
It was previously reported that synthetic PPARγ ligands bind to the canonical ligand binding pocket (LBP) and also to an alternate site on this nuclear receptor, an effect that cannot be blocked by covalently bound synthetic antagonists, demonstrating non-overlapping binding with the canonical pocket (Hughes et al., 2014) . Therefore, we performed docking experiments using crystal structures 3B0R and 5U5L deposited in the PDB. As depicted in Figure 2C, Figure 2D ), which is consistent with the fact that RGZ activates PPARγ by acting mainly through the canonical binding site (Hughes et al., 2014) . By contrast, T0070907 did not block the transcriptional activity of VCE-004.3 ( Figure 2E ). Altogether, our results strongly suggest that, in contrast to RGZ, VCE-004.3 is a PPARγ modulator (m-PPARγ) acting preferentially through the PPARγ LBP alternative binding site. In this sense, human mesenchymal stem cells treated with VCE-004.3 showed fewer and smaller lipid droplets and lower expression levels of adipogenic differentiation markers such as PPARγ, ADIPOQ and CEBPA compared to cells treated with the PPARγ full agonist (PPARγ-fa) RGZ (Supporting Information Figure S1 ). Next, we studied the effect of VCE-004.3 on CB 1 and CB 2 receptors. VCE-004.3 was able to bind CB 1 receptors with a pK i value of 5.61 ± 0.15 ( Figure 3A ) and antagonized the activity of WIN55,212 in HEK293T-CB 1 cells transfected with the pCRE-luc reporter plasmid ( Figure 3B ). VCE-004.3 also bound to CB 2 receptor-containing membranes with a pK i value of 6.69 ± 0.10 ( Figure 3C ) behaving as CB 2 agonist since it inhibited forskolin-induced luciferase activity in HEK293T-CB 2 cells transfected with the pCRE-luc reporter plasmid ( Figure 3D ). The effects of WIN55,212 and VCE-004.3 on CB 2 receptor activation were prevented by the CB 2 antagonists AM630 and SR144528 (data not shown). In summary, VCE-004.3 is a dual PPARγ/CB 2 agonist with CB 1 antagonistic activity.
VCE-004.3 prevented collagen transcription and synthesis induced by TGFβ
It has been shown that PPARγ ligands inhibit TGFβ-induced collagen gene transcription by targeting the p300 transcriptional coactivator (Ghosh et al., 2009) . Thus, we studied the effect of VCE-004.3 on collagen transcription in NIH-3T3 VCE-004.3 prevents skin fibrosis and inflammation cells stably expressing the Col1A2-luc plasmid, which encodes the gene promoter of the pro-alpha2 chain component of type I collagen fused to the luciferase gene. Pretreatment with either RGZ or VCE-004.3 resulted in a significant inhibition of collagen transcription induced by TGFβ1 stimulation ( Figure 4A ). The binding of TGFβ to its receptor entails the activation of SMAD2/SMAD3 by phosphorylation, induction of its transcriptional activity and stimulation of the Col1A2 promoter (Shi and Massague, 2003) . Pre-incubation of NIH-3T3 cells transfected with CAGA-luc plasmid with VCE.004.3 significantly reduced SMAD's transcriptional activity ( Figure 4B ). To further investigate the effect of VCE-004.3 on TGFβ1 signalling, we studied both the canonical and the ERK1/2 non-canonical pathways. As depicted in Figure 4C , VCE-004.3 did not interfere with TGFβ1-induced SMAD2 phosphorylation, but it inhibited the phosphorylation of ERK1/2 proteins in NIH-3T3 cells. Similar results were found with RGZ. Next, to correlate the effect of VCE-004.3 on Col1A2 transcriptional activity with collagen secretion and deposition, NHDFs were preincubated with increasing concentrations of VCE-004.3 and stimulated with TGFβ1 for 24 h. VCE-004.3 significantly inhibited TGFβ1-induced collagen release and accumulation in NHDFs ( Figure 4D, E) .
VCE-004.3 prevented BLM-induced dermal inflammation and fibrosis in vivo
The BLM mice model is widely used to evaluate potential anti-inflammatory and anti-fibrotic therapies for SSc (Wu et al., 2009; Gonzalez et al., 2012; del Rio et al., 2016; Ruzehaji et al., 2016) . BLM causes inflammation in a short period of time, characterized by an elevation of pro-inflammatory cytokines and growth factors that peak around day 14 of BLM exposure (Avouac, 2014) . In this model of inflammation, (C) PPARγ transcriptional activity induced by VCE-004.3 its cytotoxicity in NIH-3T3 fibroblasts. Cells were co-transfected with PPARγ-GAL4 and GAL4-luc constructs, stimulated with VCE-004.3 or RGZ as a positive control for 6 h and lysed for luciferase activity. Results are presented in a bar chart and shown as fold induction compared to control (n = 10). To test cytotoxicity, cells were treated with the compound for 6 h in the presence of YOYO-1, and fluorescence intensity was measured and presented in a dot chart (n = 5). (D and E) HEK-293T cells were co-transfected with PPARα-GAL4 (D) or PPARδ-GAL4 (E) and GAL4-luc, treated with VCE-004.3 for 6 h and lysed for luciferase activity (n = 5). Results are shown as mean ± SD. *P < 0.05 versus control.
BLM administration for 3 weeks resulted in increased dermal thickness versus the control group, which was attenuated by RGZ and VCE-004.3 treatments. However, neither RGZ nor VCE-004.3 was able to restore the loss of adipose tissue layer induced by BLM administration ( Figure 5A ). In addition, RGZ as well as VCE-004.3 were able to reduce collagen accumulation in the skin after BLM administration ( Figure 5B ). Next, we studied the expression of cytokines associated with inflammation and fibrosis. As expected, BLM-treated mice had significantly higher expression levels of Il-4, Il-6 and Ccl2 in the skin compared with control mice. This upregulation was significantly reduced in mice treated with either RGZ or VCE-004.3 ( Figure 5C ). Despite no significant changes in the expression levels of Il-1β, Tgfβ and Il-13 observed after BLM challenge, the expression of these cytokines was less in mice treated with RGZ or VCE-004.3 ( Figure 5C ).
Mast cell degranulation as well as macrophage and lymphocyte accumulation are the hallmarks of BLM-induced fibrosis and play important roles during the inflammatory phase of SSc (Yamamoto et al., 1999) . Toluidine blue staining Figure 2 VCE-004.3 competed with RGZ for the canonical pocket and binds to an alternate site in PPARγ. NIH-3T3 cells were transfected with PPARγ-GAL4 plus GAL4-luc. (A) Cells were pretreated with VCE-004.3 for 1 h and then incubated for 6 h in the presence of RGZ (n = 5). (B) Cells were pretreated with VCE-004.3 for 1 h and then washed with PBS and stimulated with RGZ for 6 h (n = 5). (C) PPARγ LBD structures 3B0R and 5U5L bound to VCE-004.3 (blue) with and without GW9662 (orange). (D and E) NIH-3T3 cells were transfected with PPARγ-GAL4 plus GAL4-luc, pretreated with T0070907 (5 μM) for 30 min and stimulated with RGZ (D) or VCE-004.3 (E) for 6 h (n = 5). Cells were lysed and tested for luciferase activity. Results are shown as mean ± SD. *P < 0.05 versus untreated cells.
showed an increased number of degranulated mast cells in the lesioned skin of the BLM group. Although we did not observe any effect in the RGZ-treated group, treatment with VCE-004.3 significantly decreased mast cell degranulation to levels comparable to the control group. Moreover, immunohistochemical examination demonstrated that VCE-004.3 significantly reduced the infiltration of F4/80 + macrophages and CD3 + lymphocytes compared with BLM untreated mice ( Figure 6 ). It is well known that TGFβ drives the conversion of fibroblasts into myofibroblasts, and the accumulation of myofibroblasts in fibrotic skin is a hallmark of SSc (Gilbane et al., 2013; Marangoni et al., 2015) . Myofibroblasts are characterized by the de novo synthesis of α-SMA fibres, and we found a substantial reduction of spindle-shaped α-SMA + cells populating the fibrotic dermis from the RGZ and VCE-004.3 treated groups ( Figure 7A ). Moreover, VCE-004.3, as well as RGZ, prevented the changes in cell morphology including cellular hypertrophy and cell shape variations from stellate to bipolar cells associated with TGFβ1-induced myofibroblast differentiation ( Figure 7B ). This was accompanied by a reduction in the steady levels of α-SMA protein; this effect was statistically significant at the dose of 10 μM ( Figure 7C ) and indicated that PPARγ ligands such as VCE-004.3 attenuate TGFβ-induced myofibroblast differentiation. It has been previously shown that disruption of the MAPK/ERK pathway reduces inflammation and fibrosis in vivo (Galuppo et al., 2011) . Therefore, we evaluated the status of phosphorylated ERK1/2 in the skin after BLM administration. Mice subjected to BLM administration showed a significant increase in ERK1/2 phosphorylation while treatment with VCE-004.3 as well as RGZ resulted in a significant decrease in p-ERK1/2 immunostaining (Figure 8 ).
VCE-004.3 alleviated established fibrosis in mice
To evaluate the efficacy of VCE-004.3 in a model of established skin fibrosis, mice were challenged with BLM for 6 weeks, and the pharmacological treatments were carried out during the last 3 weeks of BLM injections. Animals were treated with BLM alone, BLM plus RGZ (5 mg·kg À1 i.p), BLM and Il-13 were measured by q-RT-PCR. Results are presented as mean ± SEM referred to control group (n = 9 animals per group). *P < 0.05 versus control; # P < 0.05 versus BLM-treated mice.
contrast, treatment with either RGZ or VCE-004.3 (i.p. or topical) of BLM-challenged mice significantly reversed dermal thickness, although they could restore the adipose layer thickness to the control level ( Figure 9A ). According to this reduction of dermal thickness, RGZ and VCE-004.3 prevented collagen accumulation in the skin ( Figure 9B ). In a similar experiment, co-treatment with the CB 2 antagonist AM630 attenuated the effect of VCE-004.3 to a certain extent.
Figure 6
VCE-004.3 reduced inflammatory cell infiltration in the skin. Mice were injected with BLM for 3 weeks and treated in parallel with i.p. injections of RGZ, VCE-004.3 or vehicle. Representative images of the mast cell degranulation process are shown, as detected by toluidine blue staining and F4/ 80 + macrophages and CD3 + T-lymphocyte infiltration in the skin detected by immunostaining and their corresponding quantification (n = 9 animals per group). Results represent the mean ± SEM. *P < 0.05 versus control; # P < 0.05 versus BLM-treated mice.
VCE-004.3 prevents skin fibrosis and inflammation
However, the PPARγ antagonist T0070907 could not block the effect of the compound, since no significant changes in either dermal thickness or collagen accumulation were observed when compared with VCE-004.3-treated animals (Supporting Information Figure S2 ). This result confirmed that the biological activity of VCE-004.3 in vivo is mediated by targeting PPARγ at the alternative binding site as well as its effect on CB 2 receptors. The mRNA levels of Il-4, Il-6 and Tgfβ were also investigated in this model. Expression levels of Il-6 were significantly reduced with all the pharmacological treatments. Il-6 mRNA was increased in the fibrotic model, but to a much lesser extent than in the inflammatory model, indicating that the cytokine signature is different in the two approaches. Accordingly, Il-4 mRNA in the skin was not significantly increased after 6 weeks of BLM challenge, but in any case, the expression levels were reduced in both RGZ and VCE-004.3 treated mice. The expression of Tgfβ was strongly upregulated in the BLM group, and this effect was partially inhibited in VCE-004.3 (i.p.) treated mice and significantly reduced after RGZ and topical VCE-004.3 treatments ( Figure 9C ).
Effect of VCE-004.3 on ERK1/2 activation and fibroblast migration
It is well accepted that autoantibodies could play a key role in the pathogenesis of SSc. Stimulatory autoantibodies targeting the PDGF receptor have been detected in 100% of SSc patients and demonstrated to trigger an intracellular cascade that involves ROS, Ha-Ras and ERK1/2 activation, eventually leading to fibroblast activation and increased collagen gene expression (Baroni et al., 2006; Luchetti et al., 2016) . In addition, different studies have demonstrated that MAPKs are activated in response to fibrogenic stimuli and contribute to myofibroblast differentiation and function (Leask, 2012) . To study the effect of VCE-004.3 on ERK1/2 phosphorylation, NHDFs were preincubated with the compound under investigation, and then stimulated with human recombinant PDGF-BB, or with IgG purified from patients diagnosed with lcSSc or dcSSc, with the steady state levels for total and phosphorylated ERK1/2 protein being analysed by Western blots. VCE-004.3 clearly prevented ERK1/2 phosphorylation in all the condition tested ( Figure 10A-C) .
Migration of skin fibroblast plays a crucial role in SSs (Gilbane et al., 2013) , and we tested if the anti-fibrotic effect of VCE-004.3 could be associated with reduced fibroblast migration. Thus, NHDF cell monolayers were scratched, and the effect of VCE-004.3 on TGFβ1-induced wound healing was analysed over the time. Our results show that VCE-004.3 strongly inhibited the migration of fibroblasts induced by TGFβ1 ( Figure 10D ).
Discussion
We and others have previously investigated the anti-fibrotic effects of synthetic cannabinoids that activate both PPARγ and CB 2 receptors in animal models of skin fibrosis (Gonzalez et al., 2012; del Rio et al., 2016) . In this study, we report for the first time that a novel CBD derivative, VCE-004.3, which is a dual PPARγ/CB 2 agonist that also behaves as a CB 1 antagonist, exhibits both anti-inflammatory and anti-fibrotic effects.
Glitazones like RGZ are full agonists of PPARγ (PPARγ-fa) that are widely used in clinical practice for glycaemic control. Nevertheless, this kind of PPARγ-fa may cause several adverse effects, including fluid retention, congestive heart failure and bladder cancer (Ciudin et al., 2012) . Accordingly, the search for PPARγ modulators (PPARγ-m) as safer alternatives to PPARγ-fa has grown, with the expectation of separating mechanism-associated side effects from insulin-sensitizing activity. It has been demonstrated that the level of activation of PPARγ is directly related to adipogenesis but not to insulin sensitivity (Doshi et al., 2010) . PPARγ-m can bind the receptor in a different manner than PPARγ-fa, leading conformational changes that alter coactivator recruitment (Doshi et al., 2010) . In this context, VCE-004.3 can be Values are presented as mean ± SEM (n = 9 animals per group). *P < 0.05 versus control; # P < 0.05 versus BLM-treated mice. considered as a PPARγ-m, since it is less potent as an activator PPARγ than RGZ, and is less adipogenic. Here, we showed that VCE-004.3 activates PPARγ transcriptional activity and competes for the RGZ binding pocket, which is located within the PPARγ LBP. However, the effect of VCE-004.3 on PPARγ transactivation could not be blocked by T0070907 showing that both compounds bind simultaneously to distinct PPARγ binding sites, as confirmed by docking studies. These results are consistent with previous studies that reported that covalent antagonists do not block ligands that interact with the alternate binding site (Hughes et al., 2014) . Moreover, synthetic PPARγ agonists that bind to the alternate site induce PPARγ-driven anti-diabetic activities (Hughes et al., 2014) . Thus, it was not unexpected to find that T0070907 did not prevent the anti-fibrotic response of VCE-004.3 in our in vivo studies. Since PPARγ ligands that bind to canonical binding site are also effective in BLM-induced fibrosis (Wu et al., 2009; Wei et al., 2014) , we can assume that, due to the versatile nature of the LBP of PPARγ, PPARγ-ms (partial agonist) are also effective at preventing inflammation and fibrosis. It has been previously shown that the canonical pathway activated by TGFβ drives the phosphorylation of SMADs that is upstream of the fibrogenic process (Walton et al., 2017) . Our results show that VCE-004.3 reduces TGFβ-induced SMAD2/3 transcriptional activation and collagen synthesis but does not affect SMAD2/3 phosphorylation. Since ligand-mediated PPARγ activation does not interfere with the phosphorylation of SMADs, it is likely that VCE-004.3 competes with SMAD proteins for the interaction with p300 co-activator, thus preventing collagen synthesis induced by TGFβ (Ghosh et al., 2009) . However, other TGFβ-dependent signalling pathways such as the Ras/MEK/ERK cascade have also been suggested to contribute to SSc pathogenesis (Leask, 2012) . VCE-004.3 also down-regulates ERK1/2 signalling, a major pathway controlling cell growth, proliferation, migration, apoptosis and myofibroblast differentiation (McCubrey et al., 2007) . Indeed, hyperactivation of ERK1/2 was observed in fibroblasts from SSc patients, and MEK/ERK signalling is required for α-SMA stress fibre assembly (Chen et al., 2011) . Interestingly, a recent report has shown that skin fibroblasts express CB 2 receptors and that these are further upregulated under inflammatory conditions (Bort et al., 2017) . It is therefore possible that VCE-004.3 inhibits ERK1/2 activation both in vitro and in vivo by acting directly through CB 2 receptors. Accordingly, the anti-fibrotic activity of VCE.004.3 in vivo was partially prevented by the CB 2 antagonist AM630. The earliest events of SSc include obliterative vasculopathy, which induces inflammation and autoimmunity. Indeed, in early dcSSc, the dermis exhibits inflammatory infiltrates mainly composed of monocytes and activated lymphocytes (Varga and Abraham, 2007) . Accordingly, we used a model characterized by early inflammation induced by 3 weeks of BLM administration in which treatment with the compound is carried out in parallel with the BLM injections (Gonzalez et al., 2012) . Our data indicate that VCE-004.3 prevents dermal thickening as well as inflammatory cell infiltration and the expression of proinflammatory and profibrotic cytokines. Previous studies have shown that PPARγ activation by RGZ mediates immunomodulatory effects that prevent BLM-induced skin fibrosis (Wu et al., 2009) . Moreover, macrophage activation as well as T-cell proliferation are also regulated by PPARγ activation (Clark et al., 2000; Harris and Phipps, 2001 ). Indeed, activators of PPARγ and CB 2 receptors inhibited M1 polarization and influenced macrophage M2 differentiation (Bouhlel et al., 2007; Guillot et al., 2014) . Therefore, it is conceivable that PPARγ activation and modulation of the cannabinoid system by VCE-004.3 could limit leukocyte infiltration and macrophage activation in the skin after BLM administration (Akhmetshina et al., 2009; Marquart et al., 2010) .
The BLM-induced model of SSc is also useful to evaluate the progression from an inflammatory process to a fibrotic state. In this model, skin fibrosis is measured by determining dermal thickness, myofibroblast counts and collagen content, assessed by the hydroxyproline assay. Alternatively, the content of collagen in skin biopsies can be also evaluated by picrosirius staining, a semi-quantitative method, since a highly significant correlation between picrosirius staining and the results of hydroxyproline assays used to measure skin collagen have recently been found (Caetano et al., 2016) . Progressive fibrosis of the skin and other internal organs caused by excessive accumulation of collagen and other ECM is one of the three main hallmarks of SSc (Pattanaik et al., 2015) . Many compounds that have been tested using the BLM model were investigated in a preventive schedule to see if an antiinflammatory agent can hinder the subsequent fibrosis. In the event, treatment with VCE-004.3 (topical and i.p.) could reduce dermal thickness and collagen content as well as the expression of cytokines involved in collagen production after the development of fibrosis, thus alleviating the previously established damage. CB 1 and CB 2 receptors have been shown to play opposite roles in experimental models of skin fibrosis. While CB 1 receptor activation has a detrimental effect on the disease, the genetic or pharmacological inactivation of this receptor alleviates skin fibrosis. In addition, CB 2 agonists have been shown to prevent BLM-induced fibrosis (Akhmetshina et al., 2009; Marquart et al., 2010; Gonzalez et al., 2012; del Rio et al., 2016) . Thus, VCE-004.3 may have a beneficial effect on skin fibrosis by acting as a dual CB 1 antagonist and CB 2 agonist. While the CB 2 agonism effect on BLMinduced skin fibrosis has been confirmed using AM630, the potential CB 1 antagonism requires further research. We found that VCE-004.3 binds to CB 1 receptors with relatively low affinity but inhibits CB 1 -dependent cAMP signalling with a potency similar to other CB 1 antagonists. This Janus-behaviour (Dhopeshwarkar et al., 2017) could, in principle, be due to either to binding to a different site to [
3 H]-CP55940 or to it behaving as a potential negative allosteric modulator. Experiments are on course to elucidate the mechanism of action of VCE-004.3 on the functionality of CB 1 receptors. As in many autoimmune diseases, beta cell activation and generation of autoantibodies against different targets are also present in SSc patients, and this plays a critical role in the pathogenesis of the disease. Among others, agonistic PDGF receptor autoantibodies have been shown to change fibroblast phenotype into SSc features through Ha-Ras-ERK1/2 and ROS cascades (Baroni et al., 2006) . In addition, the inhibiting the activation of MAPKs has been shown to suppress the progression of fibrosis (Galuppo et al., 2011) . Treatment with VCE-004.3 prevented ERK1/2 activation in normal fibroblasts after they were exposed to stimulatory autoantibodies isolated from lcSSc and dcSSc patients, indicating that the anti-fibrotic effects of VCE-004.3 may be also mediated by ERK1/2. Interestingly, the presence of autoantibodies has been also demonstrated in the BLM model (Yamamoto, 2006) , and it is, therefore, possible that VCE-004.3 inhibits ERK1/2 activation in vivo by targeting both TGFβ-and autoantibodyinduced ERK1/2 phosphorylation.
Finally, the transdermal administration of cannabinoids is now well established (Lodzki et al., 2003; Valiveti et al., 2004) , and in this study, we have shown that topical application of VCE-004.3 also inhibited BLM-induced skin fibrosis; therefore, this compound could be also formulated for the treatment of localized forms of cutaneous fibrosis.
Cannabinoids like CBD are multitarget compounds and many semisynthetic derivatives have been designed to improve the bioactivities and druggability of the natural products. In this context, VCE-004.3 is a novel cannabinoid derivative that acts as a dual PPARγ/CB 2 agonist and as a negative modulator of CB 1 receptors. Because of this, it qualifies as a candidate for the development of novel therapies against different forms of scleroderma. Values are represented as mean ± SEM (n = 9 animals per group). *P < 0.05 versus control; #P < 0.05 versus BLM-treated mice; †P < 0.05 versus BLM + VCE-004.3.
VCE-004.3 prevents skin fibrosis and inflammation
